These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 26546213)

  • 1. 1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as potent GR antagonists with reduced hERG inhibition and an improved pharmacokinetic profile.
    Hunt HJ; Belanoff JK; Golding E; Gourdet B; Phillips T; Swift D; Thomas J; Unitt JF; Walters I
    Bioorg Med Chem Lett; 2015 Dec; 25(24):5720-5. PubMed ID: 26546213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists with high functional activity.
    Clark RD; Ray NC; Williams K; Blaney P; Ward S; Crackett PH; Hurley C; Dyke HJ; Clark DE; Lockey P; Devos R; Wong M; Porres SS; Bright CP; Jenkins RE; Belanoff J
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1312-7. PubMed ID: 18226897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Benzenesulfonyl-8a-benzyl-hexahydro-2H-isoquinolin-6-ones as selective glucocorticoid receptor antagonists.
    Clark RD; Ray NC; Blaney P; Crackett PH; Hurley C; Williams K; Dyke HJ; Clark DE; Lockey PM; Devos R; Wong M; White A; Belanoff JK
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5704-8. PubMed ID: 17822897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonists of 5-HT₆ receptors. Substituted 3-(phenylsulfonyl)pyrazolo[1,5-a]pyrido[3,4-e]pyrimidines and 3-(phenylsulfonyl)pyrazolo[1,5-a]pyrido[4,3-d]pyrimidines-Synthesis and 'structure-activity' relationship.
    Ivachtchenko AV; Golovina ES; Kadieva MG; Kysil VM; Mitkin OD; Vorobiev AA; Okun I
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4273-80. PubMed ID: 22664127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosteric modulators of the hERG K(+) channel: radioligand binding assays reveal allosteric characteristics of dofetilide analogs.
    Yu Z; Klaasse E; Heitman LH; Ijzerman AP
    Toxicol Appl Pharmacol; 2014 Jan; 274(1):78-86. PubMed ID: 24200993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of molecular modeling aided design to dial out hERG liability in adenosine A(2A) receptor antagonists.
    Deng Q; Lim YH; Anand R; Yu Y; Kim JH; Zhou W; Zheng J; Tempest P; Levorse D; Zhang X; Greene S; Mullins D; Culberson C; Sherborne B; Parker EM; Stamford A; Ali A
    Bioorg Med Chem Lett; 2015 Aug; 25(15):2958-62. PubMed ID: 26048804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules.
    Schmidtke P; Ciantar M; Theret I; Ducrot P
    J Chem Inf Model; 2014 Aug; 54(8):2320-33. PubMed ID: 25000969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel pyrrolidine melanin-concentrating hormone receptor 1 antagonists with reduced hERG inhibition.
    Fox BM; Natero R; Richard K; Connors R; Roveto PM; Beckmann H; Haller K; Golde J; Xiao SH; Kayser F
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2460-7. PubMed ID: 21414780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of tetrasubstituted imidazolines as potent and selective neuropeptide Y Y5 receptor antagonists: reduced human ether-a-go-go related gene potassium channel binding affinity and potent antiobesity effect.
    Sato N; Ando M; Ishikawa S; Jitsuoka M; Nagai K; Takahashi H; Sakuraba A; Tsuge H; Kitazawa H; Iwaasa H; Mashiko S; Gomori A; Moriya R; Fujino N; Ohe T; Ishihara A; Kanatani A; Fukami T
    J Med Chem; 2009 May; 52(10):3385-96. PubMed ID: 19459652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 5-Chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide (TAK-259) as a Novel, Selective, and Orally Active α1D Adrenoceptor Antagonist with Antiurinary Frequency Effects: Reducing Human Ether-a-go-go-Related Gene (hERG) Liabilities.
    Sakauchi N; Kohara Y; Sato A; Suzaki T; Imai Y; Okabe Y; Imai S; Saikawa R; Nagabukuro H; Kuno H; Fujita H; Kamo I; Yoshida M
    J Med Chem; 2016 Apr; 59(7):2989-3002. PubMed ID: 26954848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
    Singleton DH; Boyd H; Steidl-Nichols JV; Deacon M; Groot MJ; Price D; Nettleton DO; Wallace NK; Troutman MD; Williams C; Boyd JG
    J Med Chem; 2007 Jun; 50(13):2931-41. PubMed ID: 17536794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An automated docking protocol for hERG channel blockers.
    Di Martino GP; Masetti M; Ceccarini L; Cavalli A; Recanatini M
    J Chem Inf Model; 2013 Jan; 53(1):159-75. PubMed ID: 23259741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular docking and molecular dynamics studies on the structure-activity relationship of fluoroquinolone for the HERG channel.
    Luo F; Gu J; Chen L; Xu X
    Mol Biosyst; 2014 Nov; 10(11):2863-9. PubMed ID: 25100024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring chemical substructures essential for HERG k(+) channel blockade by synthesis and biological evaluation of dofetilide analogues.
    ; Guo D; Klaasse E; de Vries H; Brussee J; Nalos L; Rook MB; Vos MA; van der Heyden MA; Ijzerman AP
    ChemMedChem; 2009 Oct; 4(10):1722-32. PubMed ID: 19725081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect.
    Pulici M; Traquandi G; Marchionni C; Modugno M; Lupi R; Amboldi N; Casale E; Colombo N; Corti L; Fasolini M; Gasparri F; Pastori W; Scolaro A; Donati D; Felder E; Galvani A; Isacchi A; Pesenti E; Ciomei M
    ChemMedChem; 2015 Feb; 10(2):276-95. PubMed ID: 25430902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel TASK channels inhibitors derived from dihydropyrrolo[2,1-a]isoquinoline.
    Noriega-Navarro R; Lopez-Charcas O; Hernández-Enríquez B; Reyes-Gutiérrez PE; Martínez R; Landa A; Morán J; Gomora JC; Garcia-Valdes J
    Neuropharmacology; 2014 Apr; 79():28-36. PubMed ID: 24212057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of a series of 2,4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity.
    Kameda M; Kobayashi K; Ito H; Miyazoe H; Tsujino T; Nakama C; Kawamoto H; Ando M; Ito S; Suzuki T; Kanno T; Tanaka T; Tahara Y; Tani T; Tanaka S; Tokita S; Sato N
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4325-9. PubMed ID: 19487123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.
    Berglund S; Egner BJ; Gradén H; Gradén J; Morgan DG; Inghardt T; Giordanetto F
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4274-9. PubMed ID: 19500982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (3-Phenylsulfonylcycloalkano[e and d]pyrazolo[1,5-a]pyrimidin-2-yl)amines: potent and selective antagonists of the serotonin 5-HT6 receptor.
    Ivachtchenko AV; Dmitriev DE; Golovina ES; Kadieva MG; Koryakova AG; Kysil VM; Mitkin OD; Okun IM; Tkachenko SE; Vorobiev AA
    J Med Chem; 2010 Jul; 53(14):5186-96. PubMed ID: 20560595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist.
    Hunt HJ; Belanoff JK; Walters I; Gourdet B; Thomas J; Barton N; Unitt J; Phillips T; Swift D; Eaton E
    J Med Chem; 2017 Apr; 60(8):3405-3421. PubMed ID: 28368581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.